ACS boosts its commitment against cancer

October turns pink to commemorate society's commitment against breast cancer. According to figures from the Cancer Observatory of the Spanish Association Against Cancer (AECC), around 34,740 new breast cancers were diagnosed in our country in 2022, which represents almost 30% of the cancers diagnosed in women. In this context, and despite the fact that it may go unnoticed, the role played by the ACS Group in tackling the disease is crucial, as the ability to build first-rate specialized medical facilities directly impacts the results of early detection, treatment and research. 

As part of the evolution towards next-generation projects, the Group has focused on the biopharmaceutical and healthcare sector, and is already the "leading global player" and one of the leading experts in the construction of cancer treatment facilities.

In the United States, Turner was awarded at the beginning of the year a 680 million pharmaceutical plant that will contribute to the fight against the disease, while in Spain, Dragados is already a leader in the development of medical facilities.